Pharmacokinetics of lornoxicam in man.
Clinical phase I pharmacokinetic studies with lornoxicam were performed with the 4 mg dose of lornoxicam. Lornoxicam was administered as an aqueous solution both orally and intravenously to young, healthy, male volunteers. The total excretion of lornoxicam via urine and faeces after oral administration was determined by administering 14C-labelled compound. The results show that the parent compound and the main metabolite, 5'-hydroxy-lornoxicam, were found in plasma. However, in urine, no lornoxicam was detected, only 5'-hydroxy-lornoxicam. After oral as well as intravenous administration, a short terminal half-life of lornoxicam in the range of 4-5 hours was found. Given orally as solution, lornoxicam was rapidly and almost completely absorbed.
Hitzenberger
G
G
Department of Clinical Pharmacology, 1. Medizinische Universitätsklinik of Vienna, Austria.
Radhofer-Welte
S
S
Takacs
F
F
Rosenow
D
D
D000284:Administration, Oral; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004341:Drug Evaluation; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010894:Piroxicam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C059451:lornoxicam